June 8, 2021: Dr. Diana Zuckerman, president of NCHR, speaks out against FDA’s approval of the ineffective Alzheimer’s drug aduhelm.
Read More »On Medical Treatments & Products
NCHR’s Statement to FDA Advisory Committee Meeting on Neurological Devices
June 3, 2021: We urge the FDA to regulate the neurological devices in question as Class II, and require the kind of meaningful evidence for new devices that we would want for any device that we use as health professionals, as patients, or as consumers.
Read More »NCHR’s Testimony at FDA Advisory Committee Meeting on Avacopan
May 6, 2021: Although AAV is a serious disease with an unmet need for new treatments, avacopan has not clearly demonstrated that it is more effective than the existing treatments, and it apparently carries more risk for certain adverse events.
Read More »NCHR Statement at FDA Advisory Committee Meeting on Keytruda and Tecentriq for Advanced Urothelial Carcinoma
April 28, 2021: Patients have suffered from taking cancer drugs that aren’t proven to work. Other treatment options are proven to work. Physicians can still choose whatever treatments are on the market, but treatment decisions shouldn’t be based on the mistaken belief that these drugs are proven effective for advanced urothelial carcinoma.
Read More »NCHR Statement Regarding Cancer Drugs that Failed to Confirm Efficacy after Accelerated Approval
April 29, 2021: Patients are being harmed when the FDA does not follow the law pertaining to FDA approval. Drugs must be proven safe and effective, and companies must continue randomized clinical trials that prove the benefits of their drugs outweigh the risks for most patients.
Read More »